MarketPulse

POZ Platform

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Serina Therapeutics Unveils PEG-Free LNP Technology at Industry Summit

Serina's Chief Development Officer to present novel POZ-based lipid nanoparticles that eliminate PEG immunogenicity issues, showing no antibody response in preclinical studies.
PFESERbiotechnologydrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Serina Therapeutics to Showcase POZ Platform at Roth Conference

Clinical-stage biotech Serina Therapeutics will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.
PFESERclinical-stage biotechParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Serina Therapeutics

Serina Therapeutics Advances SER-252 Development With First Phase 1b Enrollee

Serina Therapeutics enrolls first patient in Phase 1b trial for SER-252, an apomorphine-based Parkinson's treatment. FDA alignment on regulatory pathway supports streamlined development timeline.
SERFDA clearancePhase 1b trial